| Dr John R Hagopian, MD | |
|
7590 Auburn Rd, Painesville, OH 44077-9176 | |
| (440) 350-0832 | |
| (440) 579-0191 |
| Full Name | Dr John R Hagopian |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 27 Years |
| Location | 7590 Auburn Rd, Painesville, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184611071 | NPI | - | NPPES |
| 2286995 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 35.081527 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lake Health | Concord, OH | Hospital |
| Lake Health Beachwood Medical Center | Beachwood, OH | Hospital |
| University Hospitals Of Cleveland | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Primary Care Practices Inc | 3072417534 | 940 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
| Entity Name | University Primary Care Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003935339 PECOS PAC ID: 3072417534 Enrollment ID: O20031125000767 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
| Entity Name | Anesthesia Associates Pll |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801823182 PECOS PAC ID: 5395648679 Enrollment ID: O20040202000866 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
| Entity Name | Ohio Anesthesia Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639348113 PECOS PAC ID: 9537222138 Enrollment ID: O20090108000069 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
| Entity Name | Radius Anesthesia Of Ohio Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427416585 PECOS PAC ID: 7113330655 Enrollment ID: O20201230001779 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
| Entity Name | Columbus Anesthesia Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801461025 PECOS PAC ID: 3678947819 Enrollment ID: O20230331002153 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John R Hagopian, MD 7757 Auburn Rd Ste 15, Painesville, OH 44077-9604 Ph: (440) 350-0832 | Dr John R Hagopian, MD 7590 Auburn Rd, Painesville, OH 44077-9176 Ph: (440) 350-0832 |
News Archive
AEterna Zentaris Inc. has presented a poster outlining Phase 1 results for its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.
Scientists have developed Australia's first adult induced pluripotent stem cell lines using skin biopsies from patients with the rare genetic disease Friedreich Ataxia.
The earlier that patients who suffer from atrial fibrillation obtain the correct treatment, the lower is the risk of serious secondary effects such as stroke. A thesis presented at the University of Gothenburg, Sweden, shows that a well-established measurement score can easily assess the risks for this patient group.
It's a longstanding question in biology: How do cells know when to progress through the cell cycle? In simple organisms such as yeast, cells divide once they reach a specific size. However, determining if this holds true for mammalian cells has been difficult, in part because there has been no good way to measure mammalian cell growth over time.
AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company's transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.
› Verified 7 days ago
Dr. Donnah W Whitaker, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7757 Auburn Rd Ste 15, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-354-7420 | |
Dr. Young Lee, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 40 W Erie St, Suite 203, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-354-7420 | |
Dr. John Joseph Scerbo, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7590 Auburn Rd, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-579-0191 | |
Dr. Christine Jordan, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 40 W Erie St, Suite 203, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-354-7420 | |
Dr. William E Cress, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 40 W Erie St, Suite 203, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-354-7420 | |
Dr. Paul Anders Bjorn, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7590 Auburn Rd, Painesville, OH 44077 Phone: 440-350-0832 Fax: 440-579-0191 |